Myelofibrosis News and Research

RSS
Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

CTI BioPharma announces upcoming presentations of pacritinib data at ASH Annual Meeting

CTI BioPharma announces upcoming presentations of pacritinib data at ASH Annual Meeting

Bristol-Myers Squibb, MD Anderson partner to evaluate multiple immunotherapies

Bristol-Myers Squibb, MD Anderson partner to evaluate multiple immunotherapies

Anti-EphA3 antibody has anti-tumour effects against solid cancers

Anti-EphA3 antibody has anti-tumour effects against solid cancers

CTI BioPharma's pacritinib granted FDA Fast Track designation for treatment of myelofibrosis

CTI BioPharma's pacritinib granted FDA Fast Track designation for treatment of myelofibrosis

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in patients with myelofibrosis

Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in patients with myelofibrosis

Blood disorder medicines could be used for treating stomach and bowel cancer

Blood disorder medicines could be used for treating stomach and bowel cancer

Study describes new tack in treatment of lung adenocarcinomas

Study describes new tack in treatment of lung adenocarcinomas

NeoGenomics launches new test for detection of mutations in CALR gene

NeoGenomics launches new test for detection of mutations in CALR gene

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

Telomerase inhibiting drug induces morphologic, molecular, clinical remissions in myelofibrosis patients

Telomerase inhibiting drug induces morphologic, molecular, clinical remissions in myelofibrosis patients

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

AMP 2013: EKF Molecular Diagnostics to launch four new PointMan DNA enrichment kits

AMP 2013: EKF Molecular Diagnostics to launch four new PointMan DNA enrichment kits

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

CTI announces publication of preclinical, clinical data for pacritinib in Drugs of the Future 2013

CTI announces publication of preclinical, clinical data for pacritinib in Drugs of the Future 2013